Canbex.co.uk - Welcome to Canbex Therapeutics
Provided by Alexa ranking,
canbex.co.uk has ranked
N/A in
N/A and
6,909,681 on the world.
canbex.co.uk reaches roughly
446 users per day and delivers about
13,390 users each month. The domain canbex.co.uk uses a Commercial suffix and it's server(s) are located in
N/A with the IP number
5.77.63.117 and it is a
.co.uk domain.
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. The goal of the Canbex lead programme is to set a new standard in the treatment of spasticity, through improved tolerability.
List of domain same IP 5.77.63.117
Search Results related to canbex.co.uk on Search Engine
-
Welcome to Canbex Therapeutics
https://www.canbex.co.uk/
Canbex Therapeutics is dedicated to discovering new medicines for rare neurological diseases. Inspired by the call of patients and their families, our mission is to build on cutting-edge research by scientific pioneers to find effective new treatments for devastating disorders of the brain and nervous system.
DA: 45 PA: 67 MOZ Rank: 44
-
Canbex Therapeutics - a client of LBIC London BioScience ...
https://www.lbic.com/canbex-therapeutics
Canbex Therapeutics is dedicated to improving the quality of life for people with multiple sclerosis through the treatment of spasticity, one of the disorder's most debilitating symptoms. The goal of the Canbex programme is to set a new standard in the treatment of spasticity, through improved tolerability.
DA: 94 PA: 57 MOZ Rank: 97
-
Canbex Therapeutics Ltd – UCLB
https://www.uclb.com/about/our-spinouts/canbex-therapeutics-ltd/
Canbex Therapeutics Ltd Canbex is a spinout of University College London (UCL) that was established to develop its proprietary VSN compound series. In addition to its pioneering scientific founders and clinical advisors, Canbex has assembled a skilled and focused management team. Development activities are carried out through leading CROs and CMOs. The company’s capital efficiency
DA: 33 PA: 30 MOZ Rank: 93
-
CANBEX THERAPEUTICS LIMITED - Overview (free company ...
https://beta.companieshouse.gov.uk/company/05073720
CANBEX THERAPEUTICS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity
DA: 73 PA: 11 MOZ Rank: 81
-
Canex - Drugs.com
https://www.drugs.com/international/canex.html
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 4 May 2020), Cerner Multum™ (updated 4 May 2020), Wolters Kluwer™ (updated ...
DA: 88 PA: 38 MOZ Rank: 43
-
Big conductance calcium-activated potassium channel ...
https://www.ncbi.nlm.nih.gov/pubmed/28677901
(9)Canbex Therapeutics Ltd, London BioScience Innovation Centre, London, UK. BACKGROUND AND PURPOSE: Our initial aim was to generate cannabinoid agents that control spasticity, occurring as a consequence of multiple sclerosis (MS), whilst avoiding the sedative side effects associated with cannabis.
DA: 72 PA: 34 MOZ Rank: 72
-
Canbex Therapeutics | Crunchbase
https://www.crunchbase.com/organization/canbex-therapeutics
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms and stiffness of limbs and torso.
DA: 21 PA: 79 MOZ Rank: 4
-
Study of VSN16R for the Treatment of Spasticity in ...
https://clinicaltrials.gov/ct2/show/NCT02542787
Canbex Therapeutics Ltd: ClinicalTrials.gov Identifier: NCT02542787 Other Study ID Numbers: CBX-001 : First Posted: September 7, 2015 Key Record Dates: Last Update Posted: March 2, 2018 Last Verified: February 2018
DA: 89 PA: 4 MOZ Rank: 92
-
Results from a phase II proof of concept trial of VSN16R ...
https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/231591/rachel.farrell.results.from.a.phase.ii.proof.of.concept.trial.of.vsn16r.to.html
Disclosure: Source of Funding: The trial was supported by Canbex Therapeutics, a semi-virtual spin-out company from University College London, using: existing Canbex assets, UCL ventures and a donation by Ipsen Pharmaceuticals as part of a pre-licencing agreement. Potential Conflicts of Interest.
DA: 80 PA: 61 MOZ Rank: 41
-
Canbex Therapeutics Ltd - Company Profile and News ...
https://www.bloomberg.com/profile/company/2610302Z:LN
Company profile page for Canbex Therapeutics Ltd including stock price, company news, press releases, executives, board members, and contact information
DA: 55 PA: 97 MOZ Rank: 67
Alexa Rank
GLOBAL RANK
Alexa Reach
Page length
Alexa Rank Country N/A
Daily Unique Visitors
Monthly Unique Visitors
Vistor via Country
Country lang
Country code
Total visitor
Country
Country code
Total visitor
Alexa Traffic Graph
Alexa daily traffic trend graph
Alexa daily pageviews (percent) graph
Alexa daily pageviews per user graph
Alexa time on site (in minutes) graph
Alexa bounce rate (percent) graph
Alexa search visits graph
SEOquake Zone
| Title |
|
Welcome to Canbex Therapeutics |
Tips |
| Description |
|
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. The goal of the Canbex lead programme is to set a new standard in the treatment of spasticity, through improved tolerability. |
Tips |
| Keywords |
|
Canbex Therapeutics, treating spasticity, Multiple Sclerosis Society, VSN16R, Phase I human safety trials. |
Tips |
| Viewport |
|
width=device-width, initial-scale=1.0 |
Tips |
| Icon |
|
|
|
| UTF-8 |
|
|
|
Mini site formation by Alexa Rank
DNS Record
| Host |
Type |
Class |
TTL |
Extra |
| canbex.co.uk |
A |
IN |
3599 |
Ip: 5.77.63.117
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns1.bdm.microsoftonline.com
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns2.bdm.microsoftonline.com
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns3.bdm.microsoftonline.com
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns4.bdm.microsoftonline.com
|
| canbex.co.uk |
SOA |
IN |
3599 |
Mname: ns1.bdm.microsoftonline.com
Rname: azuredns-hostmaster.microsoft.com
Serial: 1
Refresh: 3600
Retry: 300
Expire: 2419200
Minimum-ttl: 300
|
| canbex.co.uk |
MX |
IN |
3599 |
Pri: 0
Target: canbex-co-uk.mail.protection.outlook.com
|
| canbex.co.uk |
TXT |
IN |
3599 |
Txt: mscid=q9Rs+5Y8R81z5FLjytrAY5pTGRGqASKAo0ZoSckrW8nLDI33F5hI5zPVVH1mb61uqw/I3b/kd9ZfVFDThjds9g==
Entries_0: mscid=q9Rs+5Y8R81z5FLjytrAY5pTGRGqASKAo0ZoSckrW8nLDI33F5hI5zPVVH1mb61uqw/I3b/kd9ZfVFDThjds9g==
|
| canbex.co.uk |
TXT |
IN |
3599 |
Txt: v=spf1 include:spf.protection.outlook.com -all
Entries_0: v=spf1 include:spf.protection.outlook.com -all
|
Hosting and Whois Zone
| IP |
5.77.63.117 |
| Domain infomation |
Error: No appropriate Whois server found for canbex.co.uk domain!Error for "canbex.co.uk".
the WHOIS query quota for 104.238.132.139 has been exceeded
and will be replenished in 443 seconds
WHOIS lookup made at 21:27:45 02-Jun-2020
--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2020.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
|
